Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate.
about
Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensisAssociation between left ventricular end-diastolic pressure and coronary artery disease as well as its extent and severityLong-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus.TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- miceAssociation of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological studyRelationship between High Serum Cystatin C Levels and the Risk of Gestational Diabetes Mellitus.Association of genetic variants of the α-kinase 1 gene with myocardial infarction in community-dwelling individuals.Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular diseaseAssessment of Serum Cystatin C Levels in Newly Diagnosed Acute Myocardial Infarction at the Onset and at the Time of Hospital Discharge.Serum cystatin C and neutrophil gelatinase-associated lipocalin in predicting the severity of coronary artery disease in diabetic patients.Lack of association between cystatin C and different coronary atherosclerotic manifestations.Cystatin C, a novel cardiometabolic risk marker in women with polycystic ovary syndrome.Higher Levels of CYSTATIN C in HIV/AIDS Patients with Metabolic Syndrome.The potential of Cystatin C and small dense LDL as biomarkers of coronary artery disease risk in a young Indian population.Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly.
P2860
Q24315829-369EB685-461D-4F4C-AD05-6BBA98CE8F12Q30393917-0EB9B5B3-D296-4127-A03A-5247B7618E19Q34252954-FE3E52CE-F169-4D57-8EBD-4B703F0E51BFQ35131184-83DD31CB-6A16-4937-9ED9-6CA5933D612BQ35709080-727B5729-22A0-4380-B5C3-E36D0660435BQ35915967-4382572D-C69C-4354-8E43-262D35E86168Q37565427-919B1FF5-ED78-4246-8335-279EEBCD5F96Q37568849-1258564F-7E83-4526-940A-118061C315F1Q37629255-805098BD-C098-4E6C-95D6-842434EB002DQ37664599-CE7188FA-D7B5-4C62-A608-262AE0E92753Q38651014-8FA66A3D-9FAA-48BD-9D84-1E76748567F6Q38921697-D3222555-54FE-47F6-86B9-1F921276CDB0Q41986511-E0C03444-F057-406B-BBF6-90F104F5F2FAQ44983748-5A6931A8-6BA2-4073-9CC8-5E167ED1AC84Q50222299-0C98FC70-8FB8-49CD-999C-507522E52025
P2860
Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@ast
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@en
type
label
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@ast
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@en
prefLabel
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@ast
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@en
P2093
P2860
P356
P1476
Cystatin C and asymptomatic co ...... al glomerular filtration rate.
@en
P2093
P2860
P2888
P356
10.1186/1475-2840-11-108
P407
P577
2012-09-14T00:00:00Z
P5875
P6179
1008138809